Life Sciences

  • March 17, 2026

    Cipla To Hold Off On Pediatric Cancer Drug Generic Until 2033

    Specialty drugmaker Fennec Pharmaceuticals has jointly announced with Indian multinational pharmaceutical company Cipla Ltd. that they had reached an agreement to settle patent infringement litigation in exchange for Cipla delaying the manufacture of a generic pediatric cancer drug until 2033.

  • March 17, 2026

    Alcon Drops $430M Lensar Deal Under Pressure From FTC

    Swiss eye care company Alcon Inc. has abandoned its planned purchase of a Florida-based maker of laser treatments for cataracts, Lensar Inc., after the Federal Trade Commission threatened to block the $430 million deal.

  • March 17, 2026

    WTO Must Extend Digital Trade Protections, Lawmakers Told

    The World Trade Organization's moratorium on digital trade measures must be extended and its scope strengthened in support of U.S. business interests, experts testifying before the U.S. House's trade panel told lawmakers Tuesday.

  • March 17, 2026

    Drug Developer GNQ To Go Public Via $500M SPAC Deal

    Techbio company GNQ Insilico has announced plans to go public by merging with special-purpose acquisition company IB Acquisition Corp. in a deal that values it at $500 million and was built by four law firms.

  • March 17, 2026

    McGuireWoods Adds Former CDC Scientist From McDermott

    McGuireWoods LLP said Tuesday that it has hired a former Centers for Disease Control and Prevention scientist from McDermott Will & Schulte LLP, touting his background as a microbiologist and his history advising healthcare clients.

  • March 17, 2026

    Fenwick Healthcare Regulatory Atty Rejoins Latham In LA

    Latham & Watkins LLP is boosting its healthcare team, announcing Monday it is welcoming back a Fenwick & West LLP healthcare regulatory expert as a partner in its Los Angeles office.

  • March 16, 2026

    1st Circ. Affirms Block Of Trump's 'Unprecedented' Aid Freeze

    The First Circuit on Monday mostly upheld a lower court's order blocking the Trump administration from enacting a "sweeping and unprecedented categorical 'freeze' of federal financial assistance," ruling that the states involved in the suit will likely successfully show that the federal government acted arbitrarily and capriciously.

  • March 16, 2026

    Judge Tosses Kaiser Whistleblowers' Claims After $556M Deal

    A California federal court on Monday officially dismissed False Claims Act lawsuits from the federal government and three people alleging that Kaiser Permanente affiliates engaged in Medicare fraud, on the heels of Kaiser's $556 million settlement reached in January.

  • March 16, 2026

    Lannett Investors Seek Final OK Of $5.8M Price-Fix Probe Suit

    Former executives of pharmaceutical company Lannett Inc. and a class of investors have asked a Pennsylvania federal court to grant final approval to their $5.8 million deal to end claims the company and its leadership misled about Lannett's links to allegations of industrywide price-fixing in the market for generic drugs.

  • March 16, 2026

    J&J's Lack Of Malice Gets $966M Talc Verdict Cut To $16M

    A California state judge slashed $950 million in punitive damages from a $966 million jury verdict against Johnson & Johnson on Friday in a lawsuit involving an 88-year-old woman who died of mesothelioma, saying the estate's counsel failed to sufficiently show the pharmaceutical giant acted maliciously.

  • March 16, 2026

    Medtronic Seeks To Ax 'Extreme Outlier' $382M Antitrust Loss

    Medtronic has urged a California federal judge to scrap its nearly $382 million trial loss to rival Applied Medical over Medtronic's bundling practices that a jury found suppressed competition for advanced bipolar devices, arguing the verdict is an "extreme outlier" in antitrust law that can't survive.

  • March 16, 2026

    Amgen And Sanofi End Repatha IP Fight Heard By Justices

    Amgen Inc. and Sanofi have settled patent litigation over competing cholesterol drugs Repatha and Praluent, more than two years after they dueled at the U.S. Supreme Court, Sanofi confirmed Monday.

  • March 16, 2026

    Italy's Amplifon Buying Danish Hearing Device Biz For $2.6B

    Italy's Amplifon said Monday it has agreed to acquire the hearing device business of Denmark's GN Store Nord in a deal valuing the unit at about €2.3 billion ($2.6 billion), in a move aimed at creating a vertically integrated global leader in audiology.

  • March 16, 2026

    HHS' Childhood Vaccine Policy Changes Put On Ice

    A Massachusetts federal judge on Monday blocked the Trump administration's modified childhood vaccine schedule and put all decisions made by Health Secretary Robert F. Kennedy Jr.'s federal vaccine policy committee on hold, finding they veered sharply from normal procedure and likely violated the law.

  • March 16, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court's docket last week featured disputes including an $83.75 million settlement tied to a renewable energy merger, fraud claims in a fertilizer company acquisition and a developer's fight for control of a major Philadelphia redevelopment project.

  • March 13, 2026

    AIG Policy Excludes $150M Pollution Coverage, 7th Circ. Finds

    A Seventh Circuit panel on Friday ruled an AIG unit has no duty to cover $150 million in legal costs for Sterigenics and its former parent company following input from the Illinois Supreme Court on how to apply a pollution exclusion in the relevant policy.

  • March 13, 2026

    Maryland Bros. Get Prison For HIV Drug Fraud Scheme

    A Florida federal judge on Friday sentenced two Maryland brothers to prison for their roles in a fraudulent medication scheme that involved selling misbranded HIV drugs with fake tracing documents to pharmacies and patients. 

  • March 13, 2026

    She Has A Point: Finnegan's Cora Holt

    Cora Holt, a partner at Finnegan Henderson Farabow Garrett & Dunner LLP in Washington, D.C., has a "do your job" attitude and "getting the stuff done" approach to litigation that earned plaudits from Kassie Helm, co-chair of Dechert LLP, who praised Holt for her work as part of a Law360 series celebrating women litigators.

  • March 13, 2026

    Neuropsych Drugmaker Wants Out Of Investors' IPO Data Suit

    Neuropsychiatric drugmaker Neumora Therapeutics Inc. seeks to shed investor claims it mischaracterized certain clinical study data ahead of its September 2023 initial public offering, arguing that the trading price decline cited in the complaint was tied to results from a different study that occurred after the IPO.

  • March 13, 2026

    4th Circ. Brings Back Allergan Medicaid Overcharging Suit

    A split Fourth Circuit panel on Friday revived a whistleblower suit accusing an Allergan Sales LLC predecessor of overcharging Medicaid by more than $680 million, saying the whistleblower plausibly alleged the company knowingly improperly aggregated discounts into "best prices" for drugs.

  • March 13, 2026

    Sandoz Appealing Ruling Over Amgen's Enbrel Biosimilar

    Sandoz Inc. is appealing after a Virginia federal court ruled it should have brought claims accusing Amgen of blocking competition for the Enbrel biosimilar in a previous patent dispute, according to a Friday notice. 

  • March 13, 2026

    Kroger Agrees To Pay $17M In Drug Copay Inflation Case

    Kroger pharmacy customers reached a $17 million settlement with the grocer resolving allegations that it inflated their copays for insured prescriptions, according to a motion for preliminary approval of the deal filed in Ohio federal court.

  • March 13, 2026

    Life Sciences Partner Hiring Up Amid Regulatory Scrutiny

    Large law firms' partner additions in life sciences rose slightly across five geographic markets between 2024 and 2025, with several factors including increased regulatory scrutiny driving new additions, according to an analysis by intelligence platform Macrae+.

  • March 13, 2026

    J&J Unit Says Ex-Director Misappropriated Trade Secrets

    A Johnson & Johnson subsidiary has accused a former associate director of downloading over 7,000 files worth of confidential information prior to her resignation and using it to start her own competing company.

  • March 12, 2026

    Orthopedics Co. Investors See Merger Claims Trimmed

    Orthofix Medical Inc. must face claims that it failed to tell investors that a company it was merging with recently settled class action discrimination allegations, but will not have to face some securities fraud allegations, a Texas federal judge has ruled.

Expert Analysis

  • Series

    Building With Lego Makes Me A Better Lawyer

    Author Photo

    Building with Lego has taught me to follow directions and adapt to unexpected challenges, and in pairing discipline with imagination, allows me to stay grounded while finding new ways to make complex deals come together, says Paul Levin at Venable.

  • The Rise Of Trade Secret Specificity As A Jury Question

    Author Photo

    Recent federal appellate court decisions have clarified that determining sufficient particularity under the Defend Trade Secrets Act is a question of fact and will likely become a standard jury question, highlighting the need for appropriate jury instructions that explicitly address the issue, says Amy Candido at Simpson Thacher.

  • Series

    Law School's Missed Lessons: Networking 101

    Author Photo

    Cultivating a network isn't part of the law school curriculum, but learning the soft skills needed to do so may be the key to establishing a solid professional reputation, nurturing client relationships and building business, says Sharon Crane at Practising Law Institute.

  • Defeating Estoppel-Based Claims In Legal Malpractice Actions

    Author Photo

    State supreme court cases from recent years have addressed whether positions taken by attorneys in an underlying lawsuit can be used against them in a subsequent legal malpractice action, providing a foundation to defeat ex-clients’ estoppel claims, says Christopher Blazejewski at Sherin and Lodgen.

  • Trade Secret Rulings Reveal The Cost Of Poor Preparation

    Author Photo

    Two recent federal appellate decisions show that companies must be prepared to prove their trade secrets with specificity, highlighting how an asset management program that identifies key confidential information before litigation arises can provide the clarity and documentation that courts increasingly require, say attorneys at Mintz.

  • Series

    The Biz Court Digest: How It Works In Massachusetts

    Author Photo

    Since its founding in 2000, the Massachusetts Business Litigation Session's expertise, procedural flexibility and litigant-friendly case management practices have contributed to the development of a robust body of commercial jurisprudence, say James Donnelly at Mirick O’Connell, Felicia Ellsworth at WilmerHale and Lisa Wood at Foley Hoag.

  • Why Appellees Should Write Their Answering Brief First

    Author Photo

    Though counterintuitive, appellees should consider writing their answering briefs before they’ve ever seen their opponent’s opening brief, as this practice confers numerous benefits related to argument structure, time pressures and workflow, says Joshua Sohn at the U.S. Department of Justice.

  • Navigating DEA Quotas: Key To Psychedelics Industry Growth

    Author Photo

    As new compounds like DOI enter the Schedule I landscape, manufacturers who anticipate U.S. Drug Enforcement Administration quota regulations, and build quota management into their broader strategy, will be best equipped to meet the growing demand, say Kimberly Chew at Husch Blackwell and Jaime Dwight at Promega.

  • Series

    Mindfulness Meditation Makes Me A Better Lawyer

    Author Photo

    Mindful meditation enables me to drop the ego, and in helping me to keep sight of what’s important, permits me to learn from the other side and become a reliable counselor, says Roy Wyman at Bass Berry.

  • Growth, Harmonization In Focus As Hague System Turns 100

    Author Photo

    One hundred years after its establishment, the Hague System has grown into an important pillar of international design protection, offering a promising path toward even greater harmonization in design law as its geographic reach continues to expand, say attorneys at Sterne Kessler.

  • Lessons From 7th Circ. Decision Affirming $183M FCA Verdict

    Author Photo

    The Seventh Circuit's decision to uphold a $183 million False Claims Act award against Eli Lilly engages substantively with recurring materiality and scienter questions and provides insights into appellate review of complex trial court judgments, say Ellen London at London & Naor, Li Yu at Bernstein Litowitz and Kimberly Friday at Osborn Maledon.

  • Opinion

    Punitive Damages Awards Should Be Limited To 1st Instance

    Author Photo

    Recent verdicts in different cases against Johnson & Johnson and Monsanto showcase a trend of multiple punitive damages being awarded to different plaintiffs for the same course of conduct by a single defendant, a practice that should be deemed unconstitutional by the U.S. Supreme Court, says Jacob Mihm at Polales Horton.

  • How Calif. High Court Is Rethinking Forum Selection Clauses

    Author Photo

    Two recent cases before the California Supreme Court show that the state is shifting toward greater enforcement of freely negotiated forum selection clauses between sophisticated parties, so litigators need to revisit old assumptions about the breadth of California's public policy exception, says Josh Patashnik at Perkins Coie.

  • AI Litigation Tools Can Enhance Case Assessment, Strategy

    Author Photo

    Civil litigators can use artificial intelligence tools to strengthen case assessment and aid in early strategy development, as long as they address the risks and ethical considerations that accompany these uses, say attorneys at Barnes & Thornburg.

  • Attys Beware: Generative AI Can Also Hallucinate Metadata

    Author Photo

    In addition to the well-known problem of AI-generated hallucinations in legal documents, AI tools can also hallucinate metadata — threatening the integrity of discovery, the reliability of evidence and the ability to definitively identify the provenance of electronic documents, say attorneys at Law & Forensics.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.